NFKB1 and breast carcinoma: In breast cancer, VEGFR2 was only detected in the most aggressive subtype, triple negative breast cancer, leading to enhanced EMT (epithelial-mesenchymal transition) process and activation of NF-κB and β-catenin signaling pathways [8].